 |
|||||||
 |
 |
 |
|||||
 |
||||||||||
|
Nostrum Pharmaceuticals is engaged in the formulation and commercialization of specialty pharmaceutical products and controlled-release, orally-administered, branded and generic drugs. Nostrum has a rich portfolio of Intellectual Property. Pharmaceutical companies are increasingly utilizing controlled-release drug delivery technologies to improve therapy. These technologies allow for the development of “patient-friendly” dosage forms, which reduce frequency of drug administration, thus improving patient compliance. Controlled-release pharmaceuticals can be especially beneficial for certain patient populations, such as the elderly, who often require several medications with differing dosing regimens. (more)
Inspirx Inhalation devices, MDI's and DPI's have routinely been used by patients for symptomatic relief and treatment of patients suffering from respiratory disorders as well as systemic drug delivery. Nostrum has developed several new technologies that will leap-frog current technologies and bring new innovation in this arena. Symmetrix focuses on the development of proteins for cardiovascular diseases. (more) |
|||||||||
 |
||||||||||
© Nostrum Pharmaceuticals LLC. 2022 |
